The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management

Rheumatic Disease Clinics of North America

Volumn 43, Issue 1, 2017, Pages 95-109

  Molloy, Eamonn S ^a   Calabrese, Cassandra M ^b   Calabrese, Leonard H ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmune rheumatic diseases; Biologic therapy; Progressive multifocal leukoencephalopathy; Rituximab; Synthetic immunosuppressive therapy; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; AZATHIOPRINE; BELIMUMAB; BIOLOGICAL PRODUCT; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 7; MEFLOQUINE; MIRTAZAPINE; MYCOPHENOLIC ACID; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

AWARENESS; BRAIN BIOPSY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; FATALITY; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS REACTIVATION; BRAIN; DIAGNOSTIC IMAGING; IMMUNOCOMPROMISED PATIENT; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; RHEUMATIC DISEASES;

BIOLOGICAL PRODUCTS; BRAIN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; RHEUMATIC DISEASES;

EID: 85006240203     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2016.09.009     Document Type: Review

References (62)

1. 1 Tan, C.S., Koralnik, I.J., Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:4 (2010), 425–437.
2. 2 Johne, R., Buck, C.B., Allander, T., et al. Taxonomical developments in the family Polyomaviridae. Arch Virol 156:9 (2011), 1627–1634.
3. 3 Wollebo, H.S., White, M.K., Gordon, J., et al. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:4 (2015), 560–570.
4. 4 Brew, B.J., Davies, N.W.S., Cinque, P., et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6:12 (2010), 667–679.
5. 5 White, M.K., Khalili, K., Pathogenesis of progressive multifocal leukoencephalopathy–revisited. J Infect Dis 203:5 (2011), 578–586.
6. 6 Bayliss, J., Karasoulos, T., Bowden, S., et al. Immunosuppression increases latent infection of brain by JC polyomavirus. Pathology 43:4 (2011), 362–367.
7. 7 Bayliss, J., Karasoulos, T., McLean, C.A., Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy. J Infect Dis 207:1 (2013), 133–136.
8. 8 Berger, J.R., Khalili, K., The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med 12:67 (2011), 495–503.
9. 9 Gheuens, S., Pierone, G., Peeters, P., et al. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 81:3 (2010), 247–254.
10. 10 Tan, I.L., Koralnik, I.J., Rumbaugh, J.A., et al. Progressive multifocal leukoencephalopathy in a patient without immunodeficiency. Neurology 77:3 (2011), 297–299.
11. 11 Calabrese, L.H., Molloy, E.S., Huang, D., et al. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 56:7 (2007), 2116–2128.
12. 12 Molloy, E.S., Calabrese, L.H., Progressive multifocal leukoencephalopathy associated with biologic therapy in rheumatic diseases: strengthening association with rituximab. Arthritis Rheumatol, 66, 2014, S369.
13. 13 Calabrese, L.H., Molloy, E., Berger, J., Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol 11:2 (2015), 119–123.
14. 14 Major, E.O., Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61 (2010), 35–47.
15. 15 Durali, D., de Goër de Herve, M.G., Gasnault, J., et al. B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol, 6, 2015, 241.
16. 16 Gorelik, L., Lerner, M., Bixler, S., et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:3 (2010), 295–303.
17. 17 Clifford, D.B., Neurological immune reconstitution inflammatory response: riding the tide of immune recovery. Curr Opin Neurol 28:3 (2015), 295–301.
18. 18 Berger, J.R., The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol 24:3 (2011), 262–267.
19. 19 Lima, M.A., Drislane, F.W., Koralnik, I.J., Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66:2 (2006), 262–264.
20. 20 Küker, W., Mader, I., Nägele, T., et al. Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control. Eur J Neurol 13:8 (2006), 819–826.
21. 21 Lima, M.A., Hanto, D.W., Curry, M.P., et al. Atypical radiological presentation of progressive multifocal leukoencephalopathy following liver transplantation. J Neurovirol 11:1 (2005), 46–50.
22. 22 Rosas, M.J., Simões-Ribeiro, F., An, S.F., et al. Progressive multifocal leukoencephalopathy: unusual MRI findings and prolonged survival in a pregnant woman. Neurology 52:3 (1999), 657–659.
23. 23 Post, M.J., Yiannoutsos, C., Simpson, D., et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 20:10 (1999), 1896–1906.
24. 24 Huang, D., Cossoy, M., Li, M., et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 62:1 (2007), 34–39.
25. 25 Cinque, P., Vago, L., Dahl, H., et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 10:9 (1996), 951–958.
26. 26 Di Giambenedetto, S., Vago, G., Pompucci, A., et al. Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?. Neurology 63:12 (2004), 2452–2453.
27. 27 Martinez, J.V., Mazziotti, J.V., Efron, E.D., et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 67:9 (2006), 1692–1694.
28. 28 Langer-Gould, A., Atlas, S.W., Green, A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:4 (2005), 375–381.
29. 29 Zivanovic, M., Savšek, L., Poljak, M., et al. Possible pitfalls in the diagnostic of progressive multifocal leukoencephalopathy. Clin Neuropathol 35:2 (2016), 66–71.
30. 30 Calabrese, L.H., Molloy, E.S., Taege, A.J., Rheumatologists knowledge, attitudes and concerns regarding progressive multifocal leukoencephalopathy. Arthritis Rheum, 60(S10), 2009, 130.
31. 31 Nived, O., Bengtsson, A.A., Jönsen, A., et al. Progressive multifocal leukoencephalopathy—the importance of early diagnosis illustrated in four cases. Lupus 17:11 (2008), 1036–1041.
32. 32 Greenan, T.J., Grossman, R.I., Goldberg, H.I., Cerebral vasculitis: MR imaging and angiographic correlation. Radiology 182:1 (1992), 65–72.
33. 33 Harris, K.G., Tran, D.D., Sickels, W.J., et al. Diagnosing intracranial vasculitis: the roles of MR and angiography. AJNR Am J Neuroradiol 15:2 (1994), 317–330.
34. 34 Finelli, P.F., Onyiuke, H.C., Uphoff, D.F., Idiopathic granulomatous angiitis of the CNS manifesting as diffuse white matter disease. Neurology 49:6 (1997), 1696–1699.
35. 35 Sibbitt, W.L., Brooks, W.M., Kornfeld, M., et al. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 40:1 (2010), 32–52.
36. 36 Rituxan warning. FDA Consum, 41(2), 2007, 3.
37. 37 Molloy, E.S., Calabrese, L.H., Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60:12 (2009), 3761–3765.
38. 38 Sundsfjord, A., Osei, A., Rosenqvist, H., et al. BK and JC viruses in patients with systemic lupus erythematosus: prevalent and persistent BK viruria, sequence stability of the viral regulatory regions, and nondetectable viremia. J Infect Dis 180:1 (1999), 1–9.
39. 39 Iacobaeus, E., Hopia, L., Khademi, M., et al. Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents. Lupus 22:3 (2013), 307–311.
40. 40 Bendiksen, S., Rekvig, O.P., Van Ghelue, M., et al. VP1 DNA sequences of JC and BK viruses detected in urine of systemic lupus erythematosus patients reveal no differences from strains expressed in normal individuals. J Gen Virol 81:Pt 11 (2000), 2625–2633.
41. 41 Molloy, E.S., Calabrese, L.H., Therapy: targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol 5:8 (2009), 418–419.
42. 42 Carson, K.R., Evens, A.M., Richey, E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:20 (2009), 4834–4840.
43. 43 Tuccori, M., Focosi, D., Blandizzi, C., et al. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist 15:11 (2010), 1214–1219.
44. 44 Fleischmann, R.M., Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 60:11 (2009), 3225–3228.
45. 45 Clifford, D.B., Ances, B., Costello, C., et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68:9 (2011), 1156–1164.
46. 46 Molloy, E.S., Calabrese, L.H., Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64:9 (2012), 3043–3051.
47. 47 Houff, S.A., Berger, J.R., The bone marrow, B cells, and JC virus. J Neurovirol 14:5 (2008), 341–343.
48. 48 Fredericks, C.A., Kvam, K.A., Bear, J., et al. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus 23:7 (2014), 711–713.
49. 49 Leblanc-Trudeau, C., Masetto, A., Bocti, C., Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus. J Rheumatol 42:3 (2015), 551–552.
50. 50 Ray, M., Curtis, J.R., Baddley, J.W., A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis 73:7 (2014), 1429–1430.
51. 51 Babi, M.A., Pendlebury, W., Braff, S., et al. JC virus PCR detection is not infallible: a fulminant case of progressive multifocal leukoencephalopathy with false-negative cerebrospinal fluid studies despite progressive clinical course and radiological findings. Case Rep Neurol Med, 2015, 2015, 643216.
52. 52 Communication About an Ongoing Safety Review of CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid). U.S Food and Drug Administration. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. 2009. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm072438.htm. Accessed June 28, 2011.
53. 53 Neff, R.T., Hurst, F.P., Falta, E.M., et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 86:10 (2008), 1474–1478.
54. 54 Plavina, T., Berman, M., Njenga, M., et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol 53:1 (2012), 65–71.
55. 55 Berger, J.R., Houff, S.A., Gurwell, J., et al. JC virus antibody status underestimates infection rates. Ann Neurol 74:1 (2013), 84–90.
56. 56 Clifford, D.B., Progressive multifocal leukoencephalopathy therapy. J Neurovirol 21:6 (2015), 632–636.
57. 57 Clifford, D.B., Nath, A., Cinque, P., et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 19:4 (2013), 351–358.
58. 58 Dubey, D., Zhang, Y., Graves, D., et al. Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. Ther Adv Neurol Disord 9:3 (2016), 211–215.
59. 59 Sospedra, M., Schippling, S., Yousef, S., et al. Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 59:11 (2014), 1588–1592.
60. 60 Miskin, D.P., Chalkias, S.G., Dang, X., et al. Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia. Neurol Neuroimmunol Neuroinflamm, 3(2), 2016, e213.
61. 61 Wollebo, H.S., Bellizzi, A., Kaminski, R., et al. CRISPR/Cas9 system as an agent for eliminating polyomavirus JC infection. PLoS One, 10(9), 2015, e0136046.
62. 62 White, M.K., Kaminski, R., Wollebo, H., et al. Gene editing for treatment of neurological infections. Neurotherapeutics 13:3 (2016), 547–554.